Bharat Book Bureau Provides the Treding Market Research Report on "Acute Respiratory Distress Syndrome (ARDS) Market Insight, Epidemiology and Market Forecast -2030" under Life Sciences Category. The report offers a collection of superior market researach, market analysis, competitive intelligence and Market reports.

‘Acute Respiratory Distress Syndrome (ARDS)-Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Acute Respiratory Distress Syndrome (ARDS), historical and forecasted epidemiology as well as the Acute Respiratory Distress Syndrome (ARDS) market trends in the United States, EU5 (Germany, France, Italy, and United Kingdom) and Japan.
The Acute Respiratory Distress Syndrome (ARDS) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Acute Respiratory Distress Syndrome (ARDS) market size from 2017 to 2030. The report also covers current Acute Respiratory Distress Syndrome (ARDS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Request a Free Sample Copy Global Acute Respiratory Distress Syndrome (ARDS) Market Report@
https://www.bharatbook.com/marketreports/sample/reports/2246273

Study Period: 2017-2030
Acute Respiratory Distress Syndrome (ARDS) Disease Understanding and Treatment Algorithm
Acute Respiratory Distress Syndrome (ARDS) Overview
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The main complication in ARDS is that fluid leaks into the lungs, making breathing difficult or impossible. Acute lung injury (ALI) is a common condition characterized by acute severe hypoxia that is not due to left atrial hypertension. The term ALI encompasses a continuum of clinical and radiographic changes that affect the lungs with the acute respiratory distress syndrome (ARDS) representing the more severe end of this continuum. Despite advances in the understanding of the pathophysiology and management of ALI, it is still associated with high mortality.

The causes of ARDS are divided into two categories: direct or indirect injuries to the lung. Some of the direct injuries to the lung include pneumonia, aspiration, trauma, and others whereas the indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. The few symptoms of ARDS are shortness of breath, cough, and fever. In some cases, those with ARDS also have fast heart rates and rapid breathing. Occasionally, patients of ARDS experience chest pain, especially during inhalation. Some patients also experience bluish coloring of nails and lips due to the severely decreased oxygen levels in the blood. There are several risks factors that may escalate the risk for ARDS; this involves obesity, alcohol abuse, chemotherapy, low-protein in blood.

A novel strain of coronavirus emerged in December 2019, which was termed as COVID-19 by the World Health Organization (WHO). Coronaviruses belong to a family of viruses that range from the common cold to MERS coronavirus, which is Middle East Respiratory Syndrome and Severe acute respiratory syndrome (SARS) coronavirus. The clinical data of COVID-19 severely infected patients suggest that radiologic evidence of lung edema- a manifestation of ALI and may progress to hypoxemia and potentially ARDS-is common. The occurrence and severity of ALI are a major determining factor of the prognosis of patients with COVID‐19 infection. About 30% of patients with COVID‐19 infection in the ICU developed severe lung edema, dyspnea, hypoxemia, or even ARDS. COVID-19 patients diagnosed with ARDS have a poor prognosis and high mortality.

Acute Respiratory Distress Syndrome (ARDS) Diagnosis
The diagnosis of Acute Respiratory Distress Syndrome (ARDS) is based on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests.
ARDS is characterized by an acute, diffuse, inflammatory lung injury, leading to increased alveolar-capillary permeability, increased lung weight, and loss of aerated lung tissue. Clinically, this establishes as hypoxemia, with bilateral opacities on chest radiography, associated with reduced lung compliance and increased venous admixture and physiological dead space. Morphologically, diffuse alveolar damage is observed in the acute phase of ARDS.

Browse our full report with Table of content:
https://www.bharatbook.com/marketreports/acute-respiratory-distress-syndrome-ards-market-insight-epidemiology-and-market-forecast-2030/2246273

About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 12,00,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts, Customized Intelligence, Newsletters and Online Databases, Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.

Contact us at:
Bharat Book Bureau
Tel: +912227810772 / 27810773
Email: [email protected]
Website: www.bharatbook.com